Lilly announces new science VP and research president
This article was originally published in Scrip
Executive Summary
Lilly's executive vice–president of science and technology and president of Lilly research laboratories, Dr Steven Paul, is to retire from the company in February 2010. Dr Paul joined Lilly in 1993 and has also worked as vice–president of central nervous system discovery research and decision-phase medical research, and vice–president of therapeutic area discovery research and clinical investigation at the company. Before joining Lilly, he served as scientific director at the National Institute of Mental Health. Dr Paul will be succeeded by Dr Jan Lundberg, who has just stepped down as executive vice–president and head of global discovery research at AstraZeneca. He has been succeeded at AstraZeneca by Christer Köhler, head of global discovery for central nervous system and pain control, who has been has been appointed interim leader of discovery research until a permanent successor is found.